Overview

Famciclovir 500 mg Tablets Under Non-Fasting Conditions

Status:
Completed
Trial end date:
2004-09-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to compare the relative bioavailability of famciclovir 500 mg tablets (Novopharm Limited) with that of FAMVIR® 500 mg tablets (Novartis) in healthy adult subjects under non-fasting conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Teva Pharmaceuticals USA
Treatments:
2-Aminopurine
Famciclovir